Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT007H in Recurrent/Refractory Gastrointestinal Tumors
NCT06152757Phase 1Recruiting
- Sponsor
- Biosyngen
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGT007 in gastrointestinal tumor, sponsored by Biosyngen. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
BGT007
03
Conditions
gastrointestinal tumor
Beyond the preview
Go deeper on NCT06152757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152757.